Jefferies Group LLC set a $10.00 target price on MediWound Ltd. (NASDAQ:MDWD) in a report released on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also issued reports on MDWD. Zacks Investment Research lowered MediWound from a hold rating to a sell rating in a research report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $10.00 target price on MediWound and gave the company a buy rating in a research report on Monday, May 8th. SunTrust Banks, Inc. reissued a buy rating on shares of MediWound in a research report on Monday, June 26th. Finally, Aegis reissued a buy rating and issued a $11.00 target price on shares of MediWound in a research report on Thursday, May 25th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $9.19.

Shares of MediWound (MDWD) opened at 6.35 on Friday. MediWound has a 12 month low of $4.25 and a 12 month high of $8.58. The stock has a 50 day moving average price of $6.66 and a 200-day moving average price of $6.52. The company’s market capitalization is $139.41 million.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.01. The firm had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The firm’s revenue for the quarter was up 93.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.34) EPS. Analysts expect that MediWound will post ($0.77) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Jefferies Group LLC Analysts Give MediWound Ltd. (MDWD) a $10.00 Price Target” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/28/jefferies-group-llc-analysts-give-mediwound-ltd-mdwd-a-10-00-price-target.html.

Several large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares during the period. Wellington Management Group LLP boosted its position in shares of MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after buying an additional 342,165 shares during the period. 23.47% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.